TomTeleRx said:

Denials are usually procedural rather than clinical, and the order that works reflects that.

TomTeleRx said:

...compounded vs brand cost and coverage...

This debate comes up weekly and I think both sides have valid points:

Pro-brand: FDA-approved, manufacturing standards guaranteed, clinical trial data directly applicable

Pro-compounded: 10x cost savings, same active molecule, independent testing available, accessibility

My position: if you can afford brand or have insurance coverage, that's the gold standard. If not, properly tested compounded from a 503B pharmacy is a reasonable alternative. Neither side should shame the other.

TomTeleRx said:

Denials are usually procedural rather than clinical, and the order that works reflects that.

I read this differently from TomTeleRx, on substance rather than tone. The affordability discussion here usually stops at individual tactics. At list price this class is out of reach for most of the people who would benefit, and no amount of appeal strategy changes that — it is a pricing problem wearing a paperwork costume.

DataDave said:

The affordability discussion here usually stops at individual tactics.

Telehealth prescriber review for cost and coverage: I've used 4 different telehealth platforms to get my GLP-1 prescription. Comparison:

I settled on the one that required labs — it shows they care about safety, not just prescribing volume.

Dr.BariatricHTX said:

TomTeleRx said: ...compounded vs brand cost and coverage...

This matches mine closely enough to be worth saying so out loud. The detail I would add is minor and it is already implied above.